title: Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections.
abstract: The occurrence of infectious disease represents a failure of the immune system, a failure that must be prevented by effective vaccination or remedied by treatment. Vaccination against acute diseases such as smallpox and polio are very effective, due to the rapid and increased immune response of vaccinated individuals upon natural infection. In contrast, effective vaccination against intracellular pathogens that cause chronic diseases, such as the leishmaniases, tuberculosis and AIDS, has not been achieved. Clinical observations suggest cell-mediated, Th1 responses, exclusive of antibody production and the generation of Th2 cells, are optimally protective against these intracellular pathogens. Effective vaccination must ensure the generation of such a protective response. We explore here whether understanding very broad features of the regulation of the immune response can accommodate modern findings on the immunological features of these diseases, and provide a perspective within which strategies for effective vaccination and treatment can be developed.
authors.affiliation: Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Canada. bretschr@duke.usask.ca
authors.forename: P A
authors.initials: PA
authors.lastname: Bretsche
authors.forename: N
authors.initials: N
authors.lastname: Ismail
authors.forename: J N
authors.initials: JN
authors.lastname: Menon
authors.forename: C A
authors.initials: CA
authors.lastname: Power
authors.forename: J
authors.initials: J
authors.lastname: Uzonna
authors.forename: G
authors.initials: G
authors.lastname: Wei
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D006968:Hypersensitivity, Delayed; D007156:Immunologic Memory; D007896:Leishmaniasis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D009369:Neoplasms / Q000276:immunology; D011110:Polymorphism, Genetic; D016052:Protozoan Vaccines / Q000276:immunology / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use
chemical_list: D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D016207:Cytokines; D016052:Protozoan Vaccines; D014612:Vaccines